RECRUITING

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Arteriovenous malformation (AVM) is a congenital vascular anomaly that progresses throughout life and causes complications including tissue destruction due to rapid overgrowth, bleeding, functional deficits, severe deformity and cardiac failure. Unfortunately, traditional managements have transient benefits with more than 90 recurrence rate within a year. Therefore, there is a significant unmet medical need. The purpose of this study is to assess the safety and efficacy of Trametinib in children and adults with Extracranial Arteriovenous Malformation (AVM).

Official Title

Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM)

Quick Facts

Study Start:2020-12-01

Study Completion:2024-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04258046

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 60 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Patient must be ≥ 12 years and ≤ 60 years * Confirmed diagnosis of complicated extracranial AVMs made by a physician who is familiar with this condition. * Genetic testing for mutations within MAP2K1 or remaining RAS/MAPK pathway is preferred but not mandatory * Patient is able to swallow and/or retain oral medication via G tube * All clinical and laboratory studies to determine eligibility will be performed within six weeks prior to enrollment unless otherwise indicated. * Patients who have undergone surgical resection or interventional radiology procedures (sclerotherapy) of their AVM are eligible if they meet all inclusion criteria after these procedures * At least 4 weeks from undergoing any major surgery * Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. * Myelosuppressive chemotherapy: None within 4 weeks of entry into this study. * At least 14 days since the completion of therapy with a biologic. For agents that have known adverse events occurring beyond 14 days after administration, this period must be extended beyond the time during which adverse events are known to occur. These patients must be discussed among PI and other investigators on a case-by-case basis. * Patients must not have received an investigational drug within the prior 4 weeks. * Not within 6 months prior to entering study if AVM is within field of radiation	* AVM due to germline mutation such as PTEN * Prior MEK inhibitor therapy or have allergy or contraindication to MEK inhibitor * Unable to swallow PO drugs or administer the drug via G tube * Patients who have undergone major surgery ≤ 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedure * Patients with evidence of or history of cardiovascular risk * Patients with retinal vein occlusion, hemorrhage or have a history of such conditions. * Patients who are currently on other immunosuppressive medication(s) * Patients who have an uncontrolled infection * Unstable health status that may interfere with completing study * Unable to travel to clinic as requested * Patients unwilling or unable to comply with the protocol, or who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study. * Females of child-bearing potential must be willing to practice acceptable methods of birth control. * Additionally, females of childbearing potential must have a negative serum pregnancy test result from 7 days prior to the initiation of the medication to 3 months after the final administration of the medication. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period when they are receiving the study drug and for 3 months thereafter.

Inclusion Criteria

Exclusion Criteria

* Patient must be ≥ 12 years and ≤ 60 years
* Confirmed diagnosis of complicated extracranial AVMs made by a physician who is familiar with this condition.
* Genetic testing for mutations within MAP2K1 or remaining RAS/MAPK pathway is preferred but not mandatory
* Patient is able to swallow and/or retain oral medication via G tube
* All clinical and laboratory studies to determine eligibility will be performed within six weeks prior to enrollment unless otherwise indicated.
* Patients who have undergone surgical resection or interventional radiology procedures (sclerotherapy) of their AVM are eligible if they meet all inclusion criteria after these procedures
* At least 4 weeks from undergoing any major surgery
* Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary.
* Myelosuppressive chemotherapy: None within 4 weeks of entry into this study.
* At least 14 days since the completion of therapy with a biologic. For agents that have known adverse events occurring beyond 14 days after administration, this period must be extended beyond the time during which adverse events are known to occur. These patients must be discussed among PI and other investigators on a case-by-case basis.
* Patients must not have received an investigational drug within the prior 4 weeks.
* Not within 6 months prior to entering study if AVM is within field of radiation

* AVM due to germline mutation such as PTEN
* Prior MEK inhibitor therapy or have allergy or contraindication to MEK inhibitor
* Unable to swallow PO drugs or administer the drug via G tube
* Patients who have undergone major surgery ≤ 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedure
* Patients with evidence of or history of cardiovascular risk
* Patients with retinal vein occlusion, hemorrhage or have a history of such conditions.
* Patients who are currently on other immunosuppressive medication(s)
* Patients who have an uncontrolled infection
* Unstable health status that may interfere with completing study
* Unable to travel to clinic as requested
* Patients unwilling or unable to comply with the protocol, or who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
* Females of child-bearing potential must be willing to practice acceptable methods of birth control.
* Additionally, females of childbearing potential must have a negative serum pregnancy test result from 7 days prior to the initiation of the medication to 3 months after the final administration of the medication. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period when they are receiving the study drug and for 3 months thereafter.

Contacts and Locations

Principal Investigator

Joyce Teng, MD, PhD, FAAD

PRINCIPAL_INVESTIGATOR

Stanford University

Study Locations (Sites)

Pediatric Dermatology Clinic at Stanford Children's Hospital

Palo Alto, California, 94304

United States

Collaborators and Investigators

Sponsor: Stanford University

Joyce Teng, MD, PhD, FAAD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-12-01

Study Completion Date2024-12-31

Study Record Updates

Study Start Date2020-12-01

Study Completion Date2024-12-31

Terms related to this study

Additional Relevant MeSH Terms

Venous Malformation
Arterial Disease